Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies

Executive Summary

The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.


Related Content

Finance Watch: BIO Report Shows Record VC Funding Across Geographies
BIO-Europe Spring 2019: Themis Bioscience Harnesses Measles Vector For Immune Modulation
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch
Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines
Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
China's EpimAb Hunts For Novel Biologics With Funding, Partnerships
Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts